1.
Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for
Study
1.2.3. Key Market Segmentations
2.
Research Methodology
2.1.
Objective of
the Study
2.2.
Baseline
Methodology
2.3.
Key Industry
Partners
2.4.
Major
Association and Secondary Sources
2.5.
Forecasting
Methodology
2.6.
Data
Triangulation & Validation
2.7.
Assumptions
and Limitations
3.
Executive Summary
3.1. Overview of the
Market
3.2. Overview of Key
Market Segmentations
3.3. Overview of Key
Market Players
3.4. Overview of Key
Regions/Countries
3.5. Overview of Market
Drivers, Challenges, Trends
4.
Voice of Customer
5. Global Antisense And
RNAi Therapeutics Market Outlook
5.1.
Market Size & Forecast
5.1.1. By Value
5.2.
Market Share & Forecast
5.2.1.
By Technology (RNA Interference, Antisense RNA)
5.2.2.
By Application (Ocular, Cardiometabolic & Renal
Disorders, Cancer, Respiratory Disorders, Skin Diseases, Neurodegenerative
Disorders, Genetic Disorders, Infectious Diseases)
5.2.3.
By Route of Administration (Intravenous Injections,
Intrathecal Injections, Subcutaneous Injections, Other)
5.2.4.
By Region
5.2.5. By Company (2023)
5.3.
Market Map
5.3.1. By Technology
5.3.2. By Application
5.3.3. By Route of
Administration
5.3.4. By Region
6. Asia Pacific Antisense
And RNAi Therapeutics Market Outlook
6.1.
Market Size & Forecast
6.1.1. By Value
6.2.
Market Share & Forecast
6.2.1. By Technology
6.2.2. By Application
6.2.3. By Route of
Administration
6.2.4. By Country
6.3.
Asia Pacific: Country Analysis
6.3.1. China Antisense And
RNAi Therapeutics Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By Technology
6.3.1.2.2.
By Application
6.3.1.2.3.
By Route of Administration
6.3.2. India Antisense And
RNAi Therapeutics Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Technology
6.3.2.2.2.
By Application
6.3.2.2.3.
By Route of Administration
6.3.3. Australia Antisense
And RNAi Therapeutics Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By Technology
6.3.3.2.2.
By Application
6.3.3.2.3.
By Route of Administration
6.3.4. Japan Antisense And
RNAi Therapeutics Market Outlook
6.3.4.1.
Market Size & Forecast
6.3.4.1.1.
By Value
6.3.4.2.
Market Share & Forecast
6.3.4.2.1.
By Technology
6.3.4.2.2.
By Application
6.3.4.2.3.
By Route of Administration
6.3.5. South Korea
Antisense And RNAi Therapeutics Market Outlook
6.3.5.1.
Market Size & Forecast
6.3.5.1.1.
By Value
6.3.5.2.
Market Share & Forecast
6.3.5.2.1.
By Technology
6.3.5.2.2.
By Application
6.3.5.2.3.
By Route of Administration
7. Europe Antisense And
RNAi Therapeutics Market Outlook
7.1.
Market Size & Forecast
7.1.1. By Value
7.2.
Market Share & Forecast
7.2.1. By Technology
7.2.2. By Application
7.2.3. By
Route of Administration
7.2.4. By
Country
7.3.
Europe: Country Analysis
7.3.1. France Antisense And
RNAi Therapeutics Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Technology
7.3.1.2.2.
By Application
7.3.1.2.3.
By Route of Administration
7.3.2. Germany Antisense
And RNAi Therapeutics Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Technology
7.3.2.2.2.
By Application
7.3.2.2.3.
By Route of Administration
7.3.3. Spain Antisense And
RNAi Therapeutics Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Technology
7.3.3.2.2.
By Application
7.3.3.2.3.
By Route of Administration
7.3.4. Italy Antisense And
RNAi Therapeutics Market Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By Technology
7.3.4.2.2.
By Application
7.3.4.2.3.
By Route of Administration
7.3.5. United Kingdom
Antisense And RNAi Therapeutics Market Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By Technology
7.3.5.2.2.
By Application
7.3.5.2.3.
By Route of Administration
8. North America
Antisense And RNAi Therapeutics Market Outlook
8.1.
Market Size & Forecast
8.1.1. By Value
8.2.
Market Share & Forecast
8.2.1. By Technology
8.2.2. By Application
8.2.3. By Route of
Administration
8.2.4. By Country
8.3.
North America: Country Analysis
8.3.1. United States
Antisense And RNAi Therapeutics Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Technology
8.3.1.2.2.
By Application
8.3.1.2.3.
By Route of Administration
8.3.2. Mexico Antisense And
RNAi Therapeutics Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Technology
8.3.2.2.2.
By Application
8.3.2.2.3.
By Route of Administration
8.3.3. Canada Antisense And
RNAi Therapeutics Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Technology
8.3.3.2.2.
By Application
8.3.3.2.3.
By Route of Administration
9. South America
Antisense And RNAi Therapeutics Market Outlook
9.1.
Market Size & Forecast
9.1.1. By Value
9.2.
Market Share & Forecast
9.2.1.
By Technology
9.2.2.
By Application
9.2.3.
By Route of Administration
9.2.4. By Country
9.3.
South America: Country Analysis
9.3.1. Brazil Antisense And
RNAi Therapeutics Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Technology
9.3.1.2.2.
By Application
9.3.1.2.3.
By Route of Administration
9.3.2. Argentina Antisense
And RNAi Therapeutics Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Technology
9.3.2.2.2.
By Application
9.3.2.2.3.
By Route of Administration
9.3.3. Colombia Antisense
And RNAi Therapeutics Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Technology
9.3.3.2.2.
By Application
9.3.3.2.3.
By Route of Administration
10. Middle East and
Africa Antisense And RNAi Therapeutics Market Outlook
10.1.
Market Size & Forecast
10.1.1. By Value
10.2.
Market Share & Forecast
10.2.1.
By Technology
10.2.2.
By Application
10.2.3. By Route of Administration
10.2.4. By Country
10.3.
MEA: Country Analysis
10.3.1. South Africa
Antisense And RNAi Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1.
By Technology
10.3.1.2.2.
By Application
10.3.1.2.3.
By Route of Administration
10.3.2. Saudi Arabia
Antisense And RNAi Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1.
By Technology
10.3.2.2.2.
By Application
10.3.2.2.3.
By Route of Administration
10.3.3. UAE Antisense And
RNAi Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1.
By Technology
10.3.3.2.2.
By Application
10.3.3.2.3.
By Route of Administration
10.3.4. Egypt Antisense And
RNAi Therapeutics Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1.
By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1.
By Technology
10.3.4.2.2.
By Application
10.3.4.2.3.
By Route of Administration
11.
Market Dynamics
11.1.
Drivers
11.2.
Challenges
12.
Market Trends & Developments
12.1.
Recent Developments
12.2.
Product Launches
12.3.
Mergers & Acquisitions
13.
Global Antisense And RNAi Therapeutics Market: SWOT
Analysis
14. Porter’s Five Forces
Analysis
14.1.
Competition in the Industry
14.2.
Potential of New Entrants
14.3.
Power of Suppliers
14.4.
Power of Customers
14.5.
Threat of Substitute Product
15.
Competitive Landscape
15.1.
Olix Pharmaceuticals, Inc.
15.1.1.
Business Overview
15.1.2.
Company Snapshot
15.1.3.
Products & Services
15.1.4.
Financials (In case of listed)
15.1.5.
Recent Developments
15.1.6.
SWOT Analysis
15.2. GSK plc
15.3. Sanofi Aventis S.A.
15.4. Alnylam
Pharmaceuticals, Inc.
15.5. Ionis
Pharmaceuticals, Inc.
15.6. Benitec Biopharma
Inc
15.7. Silence Therapeutics
Inc.
15.8. Arbutus Biopharma Inc.
15.9. Sarepta Therapeutics
Inc.
15.10. Percheron
Therapeutics Limited
16. Strategic Recommendations
17. About Us & Disclaimer